(RTTNews) - Shares of Vertex Pharmaceuticals Incorporated (VRTX) are falling more than 15% Thursday morning after the company said it has decided to stop the development of its protein-deficiency drug candidate VX-814.
VX-814 was in phase II study in patients with alpha-1 antitrypsin deficiency.
Vertex Pharmaceuticals stock is currently at $229.78. It has been trading in the range of $173.62- $306.08 in the last one year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.